Leo O'Connor is a Senior Editor at 360Dx. He covers a range of topics including the Coronavirus, FDA regulations, and insights from business leaders in the markets, often focusing on the intersection of health and industry. Leo's work has been featured in LabPulse and The Science Advisory Board.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Leo O'Connor's coverage primarily focuses on healthcare and pharmaceutical industry, with an emphasis on medical testing, cancer detection, AI diagnostics, and company-specific developments such as layoffs. His articles often cite data or press releases from companies in the industry.
Leo's focus indicates a strong interest in new advancements and issues within the healthcare sector. Those who can provide insights into emerging technologies for medical testing, advancements in diagnostic tools (especially those using AI), or trends related to cancer detection may find success when reaching out to Leo.
Given his broad coverage of topics within the healthcare space and absence of a specific geographic focus, experts from various regions could engage him effectively by offering insights relevant to his areas of interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Leo O'Connor
Demand for rapid tests is tapering, and OraSure is scaling-down COVID-19 test manufacturing amid staff layoffs.
The FDA this past week continued to grant regulatory approvals for tests associated with COVID-19 that lay outside the scope of the emergency use authorization pathway.
Roche Diagnostics will showcase technologies for lab automation, the serum work area, and molecular and point-of-care solutions at an industry event; it is also unveiling a prototype for the Cobas Mass Spec system.
Working with the NIH RECOVER Initiative, researchers at Mass General Brigham have defined signature symptoms of long COVID in a prospective cohort study.
Activist investor Carl Icahn, in a proxy fight, had urged the shareholders to remove the chairman and CEO from the board.
By: Leo O'Connor
The FDA should use its authority to develop laboratory-developed test regulations if Congress does not pass legislation requiring it, said the Center for Science in the Public Interest and other organizations.
By: Leo O'Connor
The firm’s Sepsis ImmunoScore is a pathogen-agnostic, host-based digital diagnostic tool that uses artificial intelligence/machine learning to predict sepsis using clinical parameters and protein biomarkers.
Roche announced that its Cobas HPV test has been awarded WHO prequalification, expanding the cervical cancer screening tool's availability in countries that rely on the global organization’s list of prequalified suppliers to purchase tests.
By: Leo O'Connor
The firm also entered collaborations related to next-generation technology for ultra-sensitive detection of molecular residual disease (MRD) and ongoing research, as well as for the development of its multicancer early detection (MCED) approach.
Quest Diagnostics completed its previously announced acquisition of Haystack Oncology, a developer of minimal-residual disease (MRD) testing technology.
(833) 317-6278 
